Literature DB >> 16760802

Nevirapine resistance viral mutations after repeat use of nevirapine for prevention of perinatal HIV transmission.

Louise Kuhn, Moses Sinkala, M P H Chipepo Kankasa, Prisca Kasonde, Donald M Thea, Grace M Aldrovandi.   

Abstract

Mesh：

Substances：

Year:  2006        PMID： 16760802      PMCID： PMC1773052          DOI： 10.1097/01.qai.0000214820.26281.df

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  6 in total

Review 1.  Antiretroviral prophylaxis of perinatal HIV-1 transmission and the potential impact of antiretroviral resistance.

Authors:  Monica Nolan; Mary Glenn Fowler; Lynne M Mofenson
Journal:  J Acquir Immune Defic Syndr       Date:  2002-06-01       Impact factor: 3.731

2.  Impact of human immunodeficiency virus type 1 (hiv-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent hiv-1 vertical transmission (hiv network for prevention trials 012 study).

Authors:  S H Eshleman; G Becker-Pergola; M Deseyve; L A Guay; M Mracna; T Fleming; S Cunningham; P Musoke; F Mmiro; J B Jackson
Journal:  J Infect Dis       Date:  2001-08-13       Impact factor: 5.226

3.  Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

Authors:  S H Eshleman; M Mracna; L A Guay; M Deseyve; S Cunningham; M Mirochnick; P Musoke; T Fleming; M Glenn Fowler; L M Mofenson; F Mmiro; J B Jackson
Journal:  AIDS       Date:  2001-10-19       Impact factor: 4.177

4.  Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.

Authors:  Gonzague Jourdain; Nicole Ngo-Giang-Huong; Sophie Le Coeur; Chureeratana Bowonwatanuwong; Pacharee Kantipong; Pranee Leechanachai; Surabhon Ariyadej; Prattana Leenasirimakul; Scott Hammer; Marc Lallemant
Journal:  N Engl J Med       Date:  2004-07-09       Impact factor: 91.245

5.  Low frequency of the V106M mutation among HIV-1 subtype C-infected pregnant women exposed to nevirapine.

Authors:  Lynn Morris; Candice Pillay; Claudia Chezzi; Pumla Lupondwana; Matshediso Ntsala; Leon Levin; Francois Venter; Neil Martinson; Glenda Gray; James McIntyre
Journal:  AIDS       Date:  2003-07-25       Impact factor: 4.177

6.  Issues in the design of a clinical trial with a behavioral intervention--the Zambia exclusive breast-feeding study.

Authors:  Donald M Thea; Cheswa Vwalika; Prisca Kasonde; Chipepo Kankasa; Moses Sinkala; Katherine Semrau; Erin Shutes; Christine Ayash; Wei-Yann Tsai; Grace Aldrovandi; Louise Kuhn
Journal:  Control Clin Trials       Date:  2004-08
  6 in total
  3 in total

1.  HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.

Authors:  Gillian M Hunt; Ashraf Coovadia; Elaine J Abrams; Gayle Sherman; Tammy Meyers; Lynn Morris; Louise Kuhn
Journal:  AIDS       Date:  2011-07-31       Impact factor: 4.177

2.  Independent effects of nevirapine prophylaxis and HIV-1 RNA suppression in breast milk on early perinatal HIV-1 transmission.

Authors:  Michael H Chung; James N Kiarie; Barbra A Richardson; Dara A Lehman; Julie Overbaugh; Francis Njiri; Grace C John-Stewart
Journal:  J Acquir Immune Defic Syndr       Date:  2007-12-01       Impact factor: 3.731

3.  Reuse of single-dose nevirapine in subsequent pregnancies for the prevention of mother-to-child HIV transmission in Lusaka, Zambia: a cohort study.

Authors:  Jan Walter; Louise Kuhn; Chipepo Kankasa; Katherine Semrau; Moses Sinkala; Donald M Thea; Grace M Aldrovandi
Journal:  BMC Infect Dis       Date:  2008-12-30       Impact factor: 3.090
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.